About POCARD Ltd.

We are working towards the development of products for therapeutic apheresis and implementation of the technologies of therapeutic apheresis in clinical practice.

Adsorption columns of our company are used to treat a wide range of diseases in almost all fields of medicine and intended.

The goal of our company

Develop and promote the technology of therapeutic apheresis in the practical healthcare, as well as to support a high status and international recognition of the scientific results of Russian researchers in the field of extracorporeal technologies.

About
Almost 30 years of development and manufacture of the products for therapeutic apheresis;
About
Produces 7 types of adsorption columns with different specificity, which is the largest series of products among the manufacturers of adsorption columns throughout the world.
About
Conducts the full cycle of product development: from the search of a target molecule, laboratory experiments and elaboration to the commercial distribution and assistance in carrying out the procedures.
About
The first company in Russia granted with CE mark for the product of medical device.

History of the company

Date of company establishment
1992
CE mark
ISO certification
1998
Introducing products on the Russian market
2005
Nucleocor Lipopak
2020

Production

The manufacturing activity of the company is mainly devoted to the production of adsorption columns for therapeutic apheresis.

The company possesses a technology of aseptic manufacturing of products using biological components that do not require sterilization.

Image
Image
Image
Image
Certificate

Elaboration and production of adsorption columns are conducted in accordance with ISO 13485:2016 requirements and Medical Device Directive MDD 93/42/EEC.

The quality system is certified by the international audit company ITC (designated person 1023).

The quality of manufacturing and production of POCARD Ltd. in compliance with the requirements of European quality standards.

Research

The research group of POCARD Ltd. is engaged in identification of pathogenic molecules in human organism and potential targets of extracorporeal therapy useful for the treatment of different diseases.

Furthermore, our group of scientists works towards the development of synthesis methods for sorbents designed to eliminate pathogenic components from the human blood.

Image
Image
Image
Image